Preliminary Results of a Randomized Phase II Study: Treatment of Chinese Patients with Advanced Gastric Cancer with FOLFIRI Followed by FOLFOX7 or the Reverse Sequence.
F. Bi,Q. Li,C. Zhou,J. Yu,X. Cai,M. Qiu,J. Liu,C. Yi,D. Luo,F. Xu The
DOI: https://doi.org/10.1200/jco.2011.29.15_suppl.4064
IF: 45.3
2011-01-01
Journal of Clinical Oncology
Abstract:4064 Background: Two regimen sequences: folinic acid, 5-fluorouracil (FU), and irinotecan (mFOLFIRI) followed by folinic acid, FU, and oxaliplatin (mFOLFOX7; arm A), or mFOLFOX7 followed by mFOLFIRI (arm B) were evaluated for their anti-tumor activity and toxicity in Chinese patients (pts) with locally advanced and metastatic gastric cancer. METHODS Previously untreated pts with gastric or gastro-esophageal junction adenocarcinoma were randomized (1:1) to above two regimen sequences, as described in ASCO 2010 (TPS207). RESULTS 145 pts, 71 in arm A and 74 in arm B, were included between April 2008 and September 2010. Demographic characteristics were comparable (arm A vs arm B), age: 53 vs 52; M/F: 71%/29% vs 73%/27%; PS 0-1: 52% vs 53%; metastatic: 92% vs 91%; primary tumor resected: 69% vs 66%. All the pts received at least one cycle in 1st line. The 1st-line treatments were well tolerated in both arms without treatment-related death. National Cancer Institute Common Toxicity Criteria grade 3-4 neutropenia (34%) and grade 3 sensory neuropathy (12%) were more frequent with mFOLFOX7. However, pts in mFOLFIRI group experienced more grade 3 delayed diarrhea (6%) and grade 2 alopecia (45%). Other frequently reported adverse events were predominantly grade1 or 2, included thrombocytopenia, anemia, nausea, anorexia, fatigue, stomachache, mucositis, and liver function abnormalities, without difference between two arms. 32% and 34%, in arm A and arm B, respectively, of chemotherapies were delayed because of toxicity. Dose reduction was reported in 14 cases in arm A and 6 cases in arm B. CONCLUSIONS Both regimens were well-tolerated with acceptable and manageable toxicities. The first-line therapy efficacy is being followed up and will be presented at the meeting.